Hans-Göran Hårdemark

TL;DR: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score.

TL;DR: NXY-059 is ineffective for treatment of AIS within 6 hours of symptom onset and this is also true for subgroups and the prevention of alteplase-associated hemorrhage.

TL;DR: In AC-related ICH, a progressive neurological deterioration during the first 24 to 48 hours after admission is frequent, and the mortality is high, and choice of therapy to reverse the AC effect differed considerably between the hospitals.

TL;DR: Certification results suggest that use of the mRS training resource can improve mRS grading, and outline the development of a video-based training package, including technical issues, patient selection procedures, and methods of scoring and assessment.

TL;DR: NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability and was detectable early but not significant at 90 days; however, the trial was underpowered to measure effects on the neurological examination.